Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Each year on 24 March, World TB Day is commemorated to raise awareness of this devastating and deadly disease. The theme for this year’s World TB Day is “Invest to End TB. Save Lives”, conveying the urgent need to invest resources to ramp up the fight against TB and achieve the commitments to end TB made by global leaders.

Invest to end TB. Save lives. World TB Day. 
UNITE4TB's vision: supporting affected comunities with easier, faster, more effective treatment options

Despite significant progress in recent years, TB continues to be among the leading causes of death worldwide, claiming the lives of 1.5 million people per year. The COVID-19 pandemic has reversed years of global progress in tackling TB, and multidrug-resistant TB – the largest concern in the control of antimicrobial resistance globally – could put at risk the gains made over the last few decades.

TB is preventable and curable, with the right treatments and sufficient resources, it is possible to stop its spread. However, to reach the ambitious targets of 95% death reduction and 90% incidence decline set by the World Health Organization in its global strategy to end TB, more investment in TB-related activities is urgently needed.

OUCRU’S CONTRIBUTION

As a partner of UNITE4TB, we are proud to be playing our part in the fight to end TB. The Consortium is working to deliver novel phase 2 clinical trials that will accelerate the development of new anti-TB drugs and regimens. Achieving this goal will facilitate fulfillment of one of the main unmet needs in the TB field: well-tolerated drug regimens of shorter duration that can be deployed to tackle TB across various drug-resistant patterns and comorbidities.

The full story is available on the OUCRU website

Similar stories

Prof Guy Thwaites co-authored WHO’s report on antibacterial agents in preclinical & clinical development

OUCRU’s Director, Professor Guy Thwaites, has recently contributed to an analysis of antibacterial agents in preclinical and clinical development by the World Health Organisation (WHO), as part of the WHO advisory group on research and development of antibacterial treatments.

Dengue Research Article Awarded The 2021 – 2022 Alexandre Yersin Prize for Outstanding Publications

OUCRU research article titled ‘Combination of inflammatory and vascular markers in the febrile phase of dengue is associated with more severe outcomes’ was recently awarded the 2021-2022 Alexandre Yersin Prize for Outstanding Publications.

OUCRU SPEAR Digital Diaries

Healthcare workers and community members in Indonesia, Nepal and Vietnam have been documenting their personal experiences of Covid-19. They have each made their own ‘digital diary’, using a range of creative tools and with technical support from the project team. These diaries form part of the SPEAR project: exploring the experiences and impacts of COVID-19 for healthcare workers and vulnerable communities.

Clinical trials for a malaria vaccine start in Mali and Indonesia

Sanaria Inc. announced that two new Phase 2 trials of its pioneering malaria vaccines have started. The first is in 6- to 10-year-old children living in Bancoumana, Mali, a malarious region of West Africa. The second is in Indonesian soldiers based in Sumatra, Indonesia. The soldiers will be deploying for six to nine months this coming August to an intensely malarious district in eastern Indonesia.

Congratulations to our new Associate Professors

Our heartfelt congratulations to Melissa Kapulu, Francis Ndungu and Emelda Okiro from KWTRP, and to Hoa Thi Ngo and Sophie Yacoub from OUCRU who have been awarded Associate Professorships

First-of-its-kind study found equine antitoxin is safe and effective for the treatment of tetanus in adults

A first-of-its kind randomised controlled trial compared two different antitoxin treatments for tetanus. A comparison of human and equine intramuscular antitoxin in adults found that intramuscular equine antitoxin is safe and effective for treating tetanus in adults. Addition of additional intrathecal (spinal) antitoxin does not add any benefit compared to treatment with intramuscular antitoxin alone.